Holen Sie sich die Stockscreener-App
36.90
8.69%
-3.51
Handel nachbörslich:
34.00
-2.90
-7.86%
Schlusskurs vom Vortag:
$40.41
Offen:
$38.82
24-Stunden-Volumen:
84,714
Relative Volume:
2.09
Marktkapitalisierung:
$2.81B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+15.38%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$35.11
$41.20
1-Wochen-Bereich:
$20.50
$52.29
52-Wochen-Spanne:
$9.95
$52.29
Jyong Biotech Ltd Stock (MENS) Company Profile
Firmenname
Jyong Biotech Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MENS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
36.90 | 3.07B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Jyong Biotech Ltd Aktie (MENS) Neueste Nachrichten
Jyong Biotech (NASDAQ:MENS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3%Here's What Happened - MarketBeat
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain - Seeking Alpha
Jyong Biotech Ltd.'s Quiet Period Will End on July 28th (NASDAQ:MENS) - MarketBeat
Jyong Biotech Ltd. Completes Nasdaq IPO and Showcases MCS®-2 at BIO 2025 International Convention - Nasdaq
Jyong Biotech Completes Nasdaq IPO, Participates in BIO 2025 Convention. - AInvest
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention - GlobeNewswire
Taiwan's Jyong Biotech Takes On $9.8B BPH Market With Revolutionary Plant-Based Treatment After Nasdaq IPO - Stock Titan
Jyong Biotech Ltd.’s Quiet Period Set To Expire on July 28th (NASDAQ:MENS) - Defense World
Biopharma financings total $28.7B in H1, down 59% from 2024 - BioWorld MedTech
Jyong Biotech shares fall 3.33% in premarket after Wall Street Zen upgrades rating to 'hold'. - AInvest
Yong Biotech Ltd (Nasdaq:MENS) Marks Milestone at Nasdaq Composite MarketSite - Kalkine Media
Jyong Biotech shares fall 3.12% in after-hours after Wall Street Zen upgrades rating to 'hold' and CEO rings closing bell at Nasdaq. - AInvest
Pre-market Movers: BGLC, ATAI, GOVX, SNGX... - RTTNews
Jyong Biotech shares fall 4.92% in after-hours following a 34.80% surge post-Nasdaq listing and 11.04% gain over the past five days. - AInvest
Jyong Biotech shares rise 2.11% intraday as biotech sector gains and company completes $20M IPO. - AInvest
Jyong Biotech shares rise 11.82% intraday after successful $20 million IPO and addition to Nasdaq Composite Index. - AInvest
Jyong’s $20M US IPO to help refile NDA of urological botanic drug - BioWorld MedTech
Jyong Biotech Soars 11.13% Post $20M IPO - AInvest
MENSJyong Biotech Ltd. Latest Stock News & Market Updates - Stock Titan
Jyong Biotech Plunges 10.98% Despite IPO Surge - AInvest
Taiwan’s Jyong Biotech doubles in value on Nasdaq debut - Investing.com
Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering - GlobeNewswire
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle (MENS) - Seeking Alpha
MENS IPO NewsUrinary disease biotech Jyong Biotech sets terms for $19 million US IPO - renaissancecapital.com
Commercial-ready Taiwanese biotech developing therapies for urinary diseases. - renaissancecapital.com
JYB IPO NewsUrinary disease biotech Jyong Biotech withdraws $40 million US IPO - renaissancecapital.com
Jyong Biotech Ltd. Begins U.S. IPO Rollout (Pending:JYB) - Seeking Alpha
Laxton Investments Company Ltd. v. Jyong Biotech Ltd. et al: Originating Summons - OffshoreAlert
Markets Today — Quotes, Charts, and Events - TradingView
Finanzdaten der Jyong Biotech Ltd-Aktie (MENS)
Es liegen keine Finanzdaten für Jyong Biotech Ltd (MENS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):